OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple ...
SOUTH JORDAN, Utah, Sept. 16, 2025 /PRNewswire/ -- Opalescenceâ„¢ whitening, the #1-selling professional teeth whitening brand, is expanding its award-winning product lineup with the debut of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results